Amicogen, Inc. (092040.KQ)
KRW 3930.0
(-3.2%)
KRW 3930.0
(-3.2%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 70.65 Billion KRW | 42.07% |
| 2022 | 49.73 Billion KRW | 585.73% |
| 2021 | 7.25 Billion KRW | 4.32% |
| 2020 | 6.95 Billion KRW | 17.3% |
| 2019 | 5.92 Billion KRW | -5.76% |
| 2018 | 6.28 Billion KRW | 349.23% |
| 2017 | 1.4 Billion KRW | -56.92% |
| 2016 | 3.25 Billion KRW | 66.67% |
| 2015 | 1.94 Billion KRW | 0.0% |
| 2014 | - KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 84.66 Billion KRW | 9.59% |
| 2024 Q1 | 77.25 Billion KRW | 9.34% |
| 2023 Q4 | 70.65 Billion KRW | 14.31% |
| 2023 FY | 70.65 Billion KRW | 42.07% |
| 2023 Q1 | 61.12 Billion KRW | 22.91% |
| 2023 Q2 | 59.18 Billion KRW | -3.18% |
| 2023 Q3 | 61.8 Billion KRW | 4.44% |
| 2022 Q2 | 42.19 Billion KRW | 10.93% |
| 2022 Q3 | 49.56 Billion KRW | 17.46% |
| 2022 FY | 49.73 Billion KRW | 585.73% |
| 2022 Q1 | 38.03 Billion KRW | 424.51% |
| 2022 Q4 | 49.73 Billion KRW | 0.34% |
| 2021 Q2 | 9.56 Billion KRW | 44.05% |
| 2021 Q4 | 7.25 Billion KRW | -29.7% |
| 2021 Q3 | 10.31 Billion KRW | 7.79% |
| 2021 FY | 7.25 Billion KRW | 4.32% |
| 2021 Q1 | 6.64 Billion KRW | -10.83% |
| 2020 Q2 | 7.87 Billion KRW | -4.04% |
| 2020 Q3 | 7.68 Billion KRW | -2.33% |
| 2020 FY | 6.95 Billion KRW | 17.3% |
| 2020 Q1 | 8.2 Billion KRW | 18.69% |
| 2020 Q4 | 7.45 Billion KRW | -3.12% |
| 2019 Q3 | 1.99 Billion KRW | 0.52% |
| 2019 Q2 | 1.98 Billion KRW | -71.06% |
| 2019 Q1 | 6.87 Billion KRW | 9.29% |
| 2019 FY | 5.92 Billion KRW | -5.76% |
| 2019 Q4 | 6.91 Billion KRW | 245.73% |
| 2018 Q4 | 6.28 Billion KRW | -0.17% |
| 2018 Q2 | 6.85 Billion KRW | 389.29% |
| 2018 Q1 | 1.4 Billion KRW | 0.0% |
| 2018 FY | 6.28 Billion KRW | 349.23% |
| 2018 Q3 | 6.3 Billion KRW | -8.03% |
| 2017 Q3 | 1.6 Billion KRW | -64.04% |
| 2017 Q4 | 1.4 Billion KRW | -12.5% |
| 2017 FY | 1.4 Billion KRW | -56.92% |
| 2017 Q1 | 4.7 Billion KRW | 44.62% |
| 2017 Q2 | 4.45 Billion KRW | -5.32% |
| 2016 Q1 | 142.15 Million KRW | -92.71% |
| 2016 FY | 3.25 Billion KRW | 66.67% |
| 2016 Q4 | 3.25 Billion KRW | -7.14% |
| 2016 Q3 | 3.5 Billion KRW | 0.0% |
| 2016 Q2 | - KRW | -100.0% |
| 2015 Q3 | 623.19 Million KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2015 FY | 1.94 Billion KRW | 0.0% |
| 2015 Q4 | 1.94 Billion KRW | 212.89% |
| 2014 FY | - KRW | 0.0% |
| 2014 Q4 | - KRW | 0.0% |
| 2014 Q2 | - KRW | 0.0% |
| 2014 Q1 | - KRW | 0.0% |
| 2014 Q3 | - KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q3 | 1.5 Billion KRW | 0.0% |
| 2013 Q4 | - KRW | -100.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| HLB Co., Ltd. | 17.93 Billion KRW | -293.984% |
| iNtRON Biotechnology, Inc. | 258.29 Million KRW | -27253.984% |
| BINEX Co., Ltd. | 5.57 Billion KRW | -1166.573% |
| Bioneer Corporation | 12.5 Billion KRW | -465.231% |
| Anterogen.Co.,Ltd. | - KRW | -Infinity% |
| MEDIPOST Co., Ltd. | 6.99 Billion KRW | -910.075% |
| CrystalGenomics, Inc. | 29.88 Billion USD | -136.386% |
| Helixmith Co., Ltd | 151.68 Million KRW | -46480.918% |
| Chabiotech Co.,Ltd. | 95.06 Billion KRW | 25.68% |
| Medy-Tox Inc. | 1.22 Billion KRW | -5663.708% |
| Peptron, Inc. | 4.5 Billion KRW | -1470.087% |
| Genexine, Inc. | 22.68 Billion KRW | -211.506% |
| HLB Therapeutics Co.,Ltd. | 1.84 Billion KRW | -3739.491% |
| LegoChem Biosciences, Inc. | 528.37 Million KRW | -13271.988% |
| ALTEOGEN Inc. | 1.24 Billion KRW | -5555.677% |
| PharmaResearch Co., Ltd. | 970.71 Million KRW | -7178.53% |
| SillaJen, Inc. | 8.13 Billion KRW | -768.427% |
| JETEMA, Co., Ltd. | 60 Billion KRW | -17.757% |
| OliX Pharmaceuticals,Inc | 35.36 Billion KRW | -99.804% |
| Genomictree Inc. | 97.51 Million KRW | -72353.938% |
| MedPacto, Inc. | 1.68 Billion KRW | -4088.275% |
| D&D Pharmatech | 5.12 Billion KRW | -1279.792% |
| EASY BIO,Inc. | 30 Billion KRW | -135.513% |
| GI Innovation, Inc. | 2.9 Billion KRW | -2332.981% |